Lokon Pharma

Next generation cancer immunotherapeutics

Our solution

Clinical trials

LOKON001

Phase I/II study for pancreatic cancer

‍

‍

‍

Ongoing

LOKON002

Phase I/II study for patients with pancreatic-, biliary-, ovarian-, and colorectal cancer.

‍

‍

Completed

LOKON003

Phase I/II study for patients with malignant melanoma.

‍

‍

‍

Completed

Pipeline

The LOAd family includes a range of novel oncolytic viruses with different immunostimulatory genes that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).

See our pipeline

For patients

If you live in the US and have pancreatic cancer or melanoma, you may be eligible for inclusion in our clinical trials LOKON001 or LOKON003. If you live in Sweden and have pancreatic cancer, melanoma, or ovarian cancer, you may be eligible for inclusion in our clinical trials LOKON002 or LOKON003. If you are interested to participate as a study patient in our trials, please, discuss with your treating physician.

About Lokon

Lokon Pharma is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Press releases

News

Results from first pancreatic cancer trial using immunostimulatory gene therapy is published in Lancet Oncology

January 12, 2022

Lokon Pharma Initiates a Collaboration with Affibody to Develop Novel Cancer Therapeutics

August 28, 2020

Lokon Pharma Expands Collaboration with Roche Evaluating LOAd703 Immunostimulatory Gene Cancer Therapy in Combination with Tecentriq® (atezolizumab) into Colorectal Cancer

Lokon Pharma Announces Collaboration to Combine LOAd703 Oncolytic Virotherapy with Checkpoint Blockade in Pancreatic Cancer and Melanoma

January 19, 2017

First Patient Treated by a Novel Oncolytic Virus Armed with Immune Stimulators

January 23, 2020

The first clinical trial data from 13 pancreatic cancer patients treated with LOAd703 and standard of care chemotherapy was presented at GI ASCO San Fransciso. The full study Arm 1 with 18 response evaluable patients will be presented late 2021/early 2022. Arm 2 combining LOAd703, chemotherapy and checkpoint inhibition has begun to enroll patients.

October 20, 2018

Jessica Wenthe from Uppsala University presented Lokon Pharma's research at the European Society for Medical Oncology (ESMO) in Munich and was awarded the Best Poster in the immunotherapy session. Congratulations Jessica!

April 27, 2018

The first patient has been enrolled in the LOAd703 clinical trial in Sweden, LOKON002, for the treatment of pancreatic, biliary, colorectal, and ovarian cancer.

Media

Malou efter 10

Bengt fick aggressiv cancer - hade ett år kvar att leva

Barncancerfonden

Immunterapi på 100 sekunder

Malou efter 10

Forskarna om cancervaccinet: ”Behövs pengar”

Uppsala universitet

Immunterapi är ett nytt sätt att bekämpa cancer.